Amneal Pharmaceuticals, Inc. AMRX Decrease (increase) in tax receivable agreement liability
Decrease (increase) in tax receivable agreement liability at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:IncreaseDecreaseInTaxReceivableAgreementLiability.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability?
- Amneal Pharmaceuticals, Inc. (AMRX) reported decrease (increase) in tax receivable agreement liability of $2.33M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability increased by 121.8% year-over-year, from -$10.69M to $2.33M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s decrease (increase) in tax receivable agreement liability has grown at a 118.6% compound annual growth rate (CAGR), from -$631K to -$6.59M.
- What does decrease (increase) in tax receivable agreement liability mean?
- This metric tracks the periodic adjustments to the company's liability under tax receivable agreements, which typically arise from historical corporate restructuring or acquisition activities. It represents the change in the obligation to pay out future tax savings to former owners or partners. Investors monitor this to understand the impact of non-operating financial obligations on the company's cash flow and long-term debt profile.